![]() | Up a level |
Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE
ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM
ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J et al (show 24 more authors)
(2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet (London, England), 389 (10073).
1011 - 1024.
Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE
ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM
ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J et al (show 24 more authors)
(2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet (London, England), 389 (10073).
pp. 1011-1024.
Edeline, J, Blanc, J-F, Campillo-Gimenez, B, Ma, Y-T, King, J, Faluyi, O, Mathurin, J, Ghazi, S, Palmer, DH ORCID: 0000-0002-7147-5703 and Meyer, T
(2017)
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
European Journal of Cancer, 86.
pp. 135-142.